CRYOLIFE INC: insider trades · United States · SEC (Form 4)

About CRYOLIFE INC

CryoLife Inc. (ticker: CRY) is a US medical device and implantable tissue company with a long history in cardiac and vascular surgery. Although the business changed its name to Artivion in 2022, the CryoLife name still appears frequently in market data feeds, legacy references, and insider-trading/SEC-related contexts. The company is associated with the NYSE/NASDAQ market framework in the United States; historically, CRY traded on the NYSE before the ticker later changed to AORT. Founded in 1984, the company originally built its reputation around the cryogenic preservation of human heart valves for complex cardiac reconstruction, especially in children born with congenital heart defects. Over time, it broadened into a more diversified cardiovascular platform focused on aortic disease. Its headquarters are in Kennesaw, Georgia, in the Atlanta metropolitan area in the United States. The group also maintains international offices and sales infrastructure in Europe and Asia, underscoring a meaningful global footprint. CryoLife’s business model is centered on several product families: surgical sealants such as BioGlue, aortic stents and stent grafts, On-X mechanical heart valves, and cryopreserved human cardiac and vascular tissues. It also markets related surgical products and technologies used in specialized cardiovascular procedures. This mix of biologic, mechanical, and endovascular offerings gives the company exposure to a niche but strategically important segment of the medical technology market, with high regulatory, clinical, and commercial barriers. From a competitive standpoint, the company benefits from deep clinical expertise, long-standing relationships with surgeons and hospitals, and an established international distribution network. Its strategic evolution has been to sharpen its focus on aortic disease, making the equity story easier to understand for investors. Geographically, the business spans the United States, the United Kingdom, Germany, Singapore, and broader international markets, with company disclosures indicating distribution in more than 80 countries. The most notable recent milestone was the corporate rebrand to Artivion in January 2022, which signaled a clear repositioning toward aortic technologies. Prior to that, the company had completed several transformative acquisitions, including On-X Life Technologies and JOTEC, which expanded its product breadth and market reach. For French-speaking investors, CryoLife/Artivion should be viewed as a specialized US healthcare company whose performance is driven by product innovation, regulatory execution, and the global demand for advanced cardiovascular procedures.